Sanofi India Ltd vs Shelter Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3439 as of 04 May 09:48 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Shelter Pharma Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Shelter Pharma Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Shelter Pharma Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Shelter Pharma Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Shelter Pharma Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Shelter Pharma Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Shelter Pharma Ltd

Shelter Pharma Limited originally named as 'Shelter Pharmacy', was converted from a Partnership Firm 'M/s Shelter Pharma' to a Public Limited Company under the name 'Shelter Pharma Limited' on 12 October, 2007 with the Registrar of Companies, Gujarat.
Company primarily focus in manufacturing of ayurvedic and herbal products with well-built presence in Human Pharma as well as Veterinary space. The Company was founded in 1965 by Mr. N. R. Gandhi, a well-known practitioner of Ayurveda and Unani healthcare systems.
Introduction of new generation has added zeal and ambition to the company resulting in reinvention of entire company.
Aggressive and bold strategic decisions taken by the management has put it on fast growth track. The Company started with a few products about decades back.
However, over a period of time, it has added products to portfolio through in-house R & D efforts backed by sound knowledge of Ayurveda.

FAQs for the comparison of Sanofi India Ltd and Shelter Pharma Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Shelter Pharma Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Shelter Pharma Ltd is 50 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Shelter Pharma Ltd?

The stock performance of Sanofi India Ltd and Shelter Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Shelter Pharma Ltd?

As of May 4, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Shelter Pharma Ltd stock price is INR ₹30.39.

How do dividend payouts of Sanofi India Ltd and Shelter Pharma Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Shelter Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.